» Articles » PMID: 39399835

Injectable Double-crosslinked Bone Cement with Enhanced Bone Adhesion and Improved Osteoporotic Pathophysiological Microenvironment for Osteoregeneration in Osteoporosis

Overview
Journal Bioact Mater
Date 2024 Oct 14
PMID 39399835
Authors
Affiliations
Soon will be listed here.
Abstract

The osteoporotic bone defect caused by excessive activity of osteoclasts has posed a challenge for public healthcare. However, most existing bioinert bone cement fails to effectively regulate the pathological bone microenvironment and reconstruct bone homeostasis in the presence of osteoclast overactivity and osteoblast suppression. Herein, inspired by natural bone tissue, an in-situ modulation system for osteoporotic bone regeneration is developed by fabricating an injectable double-crosslinked PEGylated poly(glycerol sebacate) (PEGS)/calcium phosphate cement (CPC) loaded with sodium alendronate (ALN) (PEGS/CPC@ALN) adhesive bone cement. By incorporating ALN, the organic-inorganic interconnection within PEGS/CPC@ALN results in a 100 % increase in compression modulus and energy dissipation efficiency. Additionally, PEGS/CPC@ALN effectively adheres to the bone by bonding with amine and calcium ions present on the bone surface. Moreover, this in-situ regulation system comprehensively mitigates excessive bone resorption through the buffering effect of CPC to improve the acidic microenvironment of osteoporotic bone and the release of ALN to inhibit hyperactive osteoclasts, and facilitates stem cell proliferation and differentiation into osteoblasts through calcium ion release. Overall, the PEGS/CPC@ALN effectively regulates the pathological microenvironment of osteoporosis while promoting bone regeneration through synergistic effects of drugs and materials, thereby improving bone homeostasis and enabling minimally invasive treatment for osteoporotic defects.

Citing Articles

Drug delivery for age-related bone diseases: From therapeutic targets to common and emerging therapeutic strategies.

Bi J, Zeng J, Liu X, Mo C, Yao M, Zhang J Saudi Pharm J. 2024; 32(12):102209.

PMID: 39697472 PMC: 11653637. DOI: 10.1016/j.jsps.2024.102209.

References
1.
Kenny S, Buggy M . Bone cements and fillers: a review. J Mater Sci Mater Med. 2004; 14(11):923-38. DOI: 10.1023/a:1026394530192. View

2.
He Z, Sun C, Ma Y, Chen X, Wang Y, Chen K . Rejuvenating Aged Bone Repair through Multihierarchy Reactive Oxygen Species-Regulated Hydrogel. Adv Mater. 2023; 36(9):e2306552. DOI: 10.1002/adma.202306552. View

3.
Russell R, Xia Z, Dunford J, Oppermann U, Kwaasi A, Hulley P . Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007; 1117:209-57. DOI: 10.1196/annals.1402.089. View

4.
Lin X, Wang Q, Gu C, Li M, Chen K, Chen P . Smart Nanosacrificial Layer on the Bone Surface Prevents Osteoporosis through Acid-Base Neutralization Regulated Biocascade Effects. J Am Chem Soc. 2020; 142(41):17543-17556. DOI: 10.1021/jacs.0c07309. View

5.
Lin J . Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; 18(2):75-85. DOI: 10.1016/8756-3282(95)00445-9. View